Cited by 697Statistical Methods in Clinical TrialsEthics in Clinical ResearchPharmaceutical industry and healthcare

The DOI matches its Crossref record.

Phase II and Phase III attrition rates 2011–2012

Arrowsmith, John, Miller, Philip·2013·Nature Reviews Drug Discovery

DOI 10.1038/nrd4090

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nrd4090

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 401–500 of 697

MemCross: Accelerated Weight Histogram method to assess membrane permeability
Benmameri, M., Chantemargue, B., Humeau, A., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2023.184120 · Cited by 8
Mechanistic investigation of liver injury induced by BMS-932481, an experimental ɣ-secretase modulator
Zhuo, X., Howell, B. A., Shen, H., Woodhead, J. L., Mosure, K., Zhang, Y., Scialis, R. J., Iyer, R. A., Sun, Y., Boy, K. M., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad057 · Cited by 8
Genetic Rat Models for Schizophrenia
Ellenbroek, B. A., & Karl, T. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00018-3 · Cited by 8
Etablierung einer Living Biobank
Pauli, C., Moch, H., & Rubin, M. A. (2017) · Der Pathologe · doi:10.1007/s00292-017-0346-1 · Cited by 8
Disease Modeling of Mitochondrial Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells
Tokuyama, T., Ahmed, R. E., Chanthra, N., Anzai, T., & Uosaki, H. (2021) · Biology · doi:10.3390/biology10100981 · Cited by 8
“Approximately 30% of drug candidates discontinue due to safety issues during their clinical development phases, with most being excluded due to cardiovascular side effects [13].”
Background
Adeno-Associated Virus Gene Therapy Development: Early Planning and Regulatory Considerations to Advance the Platform Vector Gene Therapy Program
Lomash, R. M., Dehdashti, J., Shchelochkov, O. A., Chandler, R. J., Li, L., Manoli, I., Sloan, J. L., Terse, P., Xu, X., Saade, D. N., et al. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.230 · Cited by 7
IMPACT Framework: Establishing Global Standards for Artificial Intelligence Implementation, Methodology, and Translation in Drug Discovery
Gangwal, A., & Lavecchia, A. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70072 · Cited by 9
HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B
Kapr, J., Scharkin, I., Ramachandran, H., Westhoff, P., Pollet, M., Dangeleit, S., Brockerhoff, G., Rossi, A., Koch, K., Krutmann, J., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05406-w · Cited by 10
“Drugs developed for CNS diseases display the second highest attrition rates right after cancer drugs with causes of drug failure allocating to lack of efficacy and second most frequently to toxicity [55].”
Background
Establishment of an in Vitro Three-Dimensional Vascularized Micro-Tumor Model and Screening of Chemotherapeutic Drugs
Ye, Q., Wang, J., Wang, B., Zhao, M., Wu, Z., & Liu, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241286755 · Cited by 6
Drug repurposing and beyond: the fundamental role of pharmacology
Amantea, D. (2015) · Functional Neurology · doi:10.11138/fneur/2015.30.1.079 · Cited by 7
“, phase II) were found to be significantly increased, while those in phase III were reduced, nevertheless standing at around 52% (Arrowsmith and Miller, 2013).”
Background
Model‐based prediction of progression‐free survival for combination therapies in oncology
Baaz, M., Cardilin, T., & Jirstrand, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13003 · Cited by 7
“5,6 Therefore, more research is needed to support early and accurate identification of promising new anticancer candidates and combinations.”
Background
A plan for sustainable funding for US biomedical research
Hensley, P., & LaMattina, J. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4454-c1 · Cited by 7
Patient-centered drug discovery as the means to improved R&D productivity
Raoof, A. A., & Aerssens, J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.002 · Cited by 7
Modular multi-organ-on-chips platform with physicochemical sensor integration
Zhang, Y. S. (2017) · IEEE International Midwest Symposium on Circuits and Systems (MWSCAS) · doi:10.1109/mwscas.2017.8052865 · Cited by 8
Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models
Kiani, Y. S., & Jabeen, I. (2019) · Computation · doi:10.3390/computation7020026 · Cited by 7
Three‐dimensional in vitro cell culture devices using patient‐derived cells for high‐throughput screening of drug combinations
Kwon, S., Lee, D., Gopal, S., Ku, A., Moon, H., & Dordick, J. S. (2020) · Medical Devices & Sensors · doi:10.1002/mds3.10067 · Cited by 7
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
Mao, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93093 · Cited by 11
Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?
Drukarch, B., Jacobs, G. E., & Wilhelmus, M. M. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110545 · Cited by 7
New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth
Sagara, A., Nakata, K., Yamashita, T., Guan, W., Zhong, P., Matsumoto, S., Endo, S., Iwamoto, C., Shindo, K., Ikenaga, N., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.04.002 · Cited by 7
Phenotypic Screening
Plowright, A. T., & Drowley, L. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.07.001 · Cited by 7
Primate autoimmune disease models; lost for translation?
Hart, B. A. ‘. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.82 · Cited by 7
Attrition in Drug Discovery and Development
Boyer, S. K., BREALEY, C. J., & Davis, A. M. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch1 · Cited by 7
Neuroprotective Potential of L-Glutamate Transporters in Human Induced Pluripotent Stem Cell-Derived Neural Cells against Excitotoxicity
Takahashi, K., Ishibashi, Y., Chujo, K., Suzuki, I., & Sato, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612605 · Cited by 7
PET Imaging of Peptide Probe Al[18F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors
Zhang, Y., Wang, Y., Chen, Y., Ding, X., Wang, S., Liu, W., Hu, M., & Liu, Z. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01151 · Cited by 6
Transporter expressions as part of required scaling factor to support in vitro in vivo extrapolation for blood-brain barrier drug permeability
Al‐Majdoub, Z. M., Cheong, J., Mizuno, K., Hogan, J., Bruyn, T. D., Kanta, A., Guo, J., Hop, C. E. C. A., Zientek, M., Galetin, A., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107022 · Cited by 7
Heart-on-a-chip
Gaudriault, P., Fassini, D., & Homs-Corbera, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00008-5 · Cited by 7
Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine
Liu, C., Shi, C., Wang, S., Qi, R., Gu, W., Yu, F., Zhang, G., & Qiu, F. X. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1554268 · Cited by 10
A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation
McShane, M. P., Friedrichson, T., Giner, A., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115579613 · Cited by 6
“The delivery of new drugs to the market has been declining in past years because of failures in clinical phase II and III trials that have caused a concomitant increase in the costs of drug development.(1) Part of the problem in drug discovery lies in the difficulty of analyzing how cellular networks are regulated, in…”
Prediction of Active Drug Molecule using Back-Propagation Neural Network
Mandal, L., & Jana, N. D. (2019) · doi:10.1109/smart46866.2019.9117378 · Cited by 6
“Basic Concepts of CADD Traditional Drug Design (TDD) process needs very long time and huge cost but very few drug discovery projects release a new drug that implies the success rate of TDD is very less [5] [6].”
Background
Engineering multicellular living systems—a Keystone Symposia report
Cable, J., Arlotta, P., Parker, K. K., Hughes, A. J., Goodwin, K., Mummery, C. L., Kamm, R. D., Engle, S. J., Tagle, D. A., Boj, S. F., et al. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14896 · Cited by 6
How to think about and do successful research What you probable did not learn when you first entered the laboratory
Cooper, T. (2023) · FEMS Yeast Research · doi:10.1093/femsyr/foac065 · Cited by 5
The changing world of cancer drug development: the regulatory bodies' perspective.
Gravanis, I., Vleminckx, C., Jönsson, B., & Pignatti, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.08 · Cited by 6
“So far, these approaches have delivered some success but also a lot of failures, with high attrition rates during development reported by the pharmaceutical industry (2,3).”
Background
Computational Models to Predict Toxicological Endpoints in Drug Discovery and Strategies for Data Integration
Brigo, A., & Muster, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12321-2 · Cited by 6
The application of electrophysiological methods to characterize AMPA receptors in dissociated adult rat and non-human primate cerebellar neurons for use in neuronal safety pharmacology assessments of the central nervous system
Miraucourt, L. S., Accardi, M. V., Asin, K. E., Pugsley, M. K., Curtis, M. J., & Authier, S. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106883 · Cited by 6
EK-DRD: A Comprehensive Database for Drug Repositioning Inspired by Experimental Knowledge
Zhao, C., Dai, X., Li, Y., Guo, Q., Zhang, J., Zhang, X., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00365 · Cited by 6
A Brainer on Neurotoxicity
Fritsche, E., & Högberg, H. T. (2020) · Frontiers in Toxicology · doi:10.3389/ftox.2020.00003 · Cited by 6
“, 2016) and for central nervous system (CNS) drugs specifically (Arrowsmith and Miller, 2013; DiMasi, 2014; Harrison, 2016;Mohs andGreig, 2017), were attributed to insufficient human predictability of nonclinical biological data, i.”
Background
How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development
Schäfer‐Korting, M., & Zoschke, C. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_374 · Cited by 6
Harnessing confounding and genetic pleiotropy to identify causes of disease through proteomics and Mendelian randomisation – ‘MR Fish’Preprint
Warwick, A., Hingorani, A. D., Khawaja, A. P., Gordillo‐Marañón, M., Olvera‐Barrios, A., Stuart, K. V., Egan, C. A., Tufail, A., Sofat, R., Kuan, V., et al. (2024) · medRxiv · doi:10.1101/2024.07.11.24310200 · Cited by 4
F.O.R.W.A.R.D: A Data-Driven Framework for Network-Based Target Prioritization in Drug DiscoveryPreprint
Sinha, S., McLaren, E., Mullick, M., Penrose, H. M., Tindle, C., Singh, S., Boland, B. S., & Ghosh, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.16.602603 · Cited by 6
Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – A Modeling Approach
Xu, M., Sun, D., & An, G. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00979-7 · Cited by 5
Gossypol is a natural product with good antimalarial activity against Plasmodium falciparum clinical isolates
Chirawurah, J. D., Ansah, F., Blankson, S. O., Adikah, B., Yeboah, S. N., Amenga-Etego, L. N.-K., Awandare, G. A., & Aniweh, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-85643-6 · Cited by 6
In situ single-cell therapeutic response imaging facilitated by the TRIPODD fluorescence imaging platform
McMahon, N. P., Solanki, A., Wang, L. G., Montaño, A. R., Jones, J. A., Samkoe, K. S., Tichauer, K. M., & Gibbs, S. L. (2024) · Theranostics · doi:10.7150/thno.93256 · Cited by 6
Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease
Finkbeiner, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105088 · Cited by 8
Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
Rossi, A., Pilotto, S., Carbognin, L., Ferrara, M. G., Belluomini, L., Daniele, G., & Bria, E. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2030018 · Cited by 5
“In oncology research, the clinical trials can fail more frequently than in any other diseases [1].”
Background
The Impact of Cellular Environment on In Vitro Drug Screening
Moldasheva, A., Bakyt, L., Bulanin, D. S., & Aljofan, M. (2023) · Future Science OA · doi:10.2144/fsoa-2023-0027 · Cited by 6
Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models
Goldring, C. E., Norris, A. M., Kitteringham, N. R., Aleo, M. D., Antoine, D. J., Heslop, J. A., Howell, B. A., Ingelman‐Sundberg, M., Kia, R., Kamalian, L., et al. (2015) · Applied In Vitro Toxicology · doi:10.1089/aivt.2015.0001 · Cited by 5
“8 This ﬁgure rises to 35% in phase III, representing an enormous ﬁnancial impact on the pharmaceutical industry.”
Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models
Brigo, A., Naga, D., & Muster, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_24 · Cited by 5
CSL-Tox: an open-source analytical framework for the comparison of short-term and long-term toxicity end points and assessing the need of chronic studies in drug development
Naga, D., Dimitrakopoulou, S., Roberts, S., Husar, E., Mohr, S., Booler, H. S., & Musvasva, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-41899-4 · Cited by 5
“For Compound-7 [4 w, 26 w] axonal degeneration was observed in the long-term study and was minimal.”
Background
Advanced Human In vitro Models for the Discovery and Development of Lung Cancer Therapies
Constant, S., Huang, S., Wisniewski, L., & Mas, C. (2015) · InTech eBooks · doi:10.5772/60606 · Cited by 5
“Unfortunately, this difficult therapeutic area has shown the highest failure rate in clinical trials over the last 30 years [2] and hitherto, there is no effective treatment for patients with lung cancer.”
Background
In vivo MR in the drug pipeline
Evelhoch, J. L. (2018) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2018.04.012 · Cited by 5
Human pluripotent stem cell–based cardiovascular disease modeling and drug discovery
Liu, G., Liu, Z., & Cao, N. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02542-1 · Cited by 5
The New Serum-Free OptiPASS® Medium in Cold and Oxygen-Free Conditions: An Innovative Conservation Method for the Preservation of MDA-MB-231 Triple Negative Breast Cancer Spheroids
Goisnard, A., Dubois, C., Daumar, P., Aubel, C., Depresle, M., Gauthier, J. B., Vidalinc, B., Penault-Llorca, F. M., Mounetou, E., & Bamdad, M. (2021) · Cancers · doi:10.3390/cancers13081945 · Cited by 5
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists
van Veldhoven, J. P. D., Liu, R., Thee, S. A., Wouters, Y., Verhoork, S. J. M., Mooiman, C., Louvel, J., & IJzerman, A. P. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.018 · Cited by 5
The Use of In Silico Models Within a Large Pharmaceutical Company
Brigo, A., & Muster, W. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3609-0_20 · Cited by 6
Minimizing Bias in Target Selection by Exploiting Multidisciplinary Big Data and the Protein Interactome
Al‐Lazikani, B., & Workman, P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0133 · Cited by 5
Statistical Innovations in Cancer Research
Lee, J. J., & Berry, D. A. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm020.pub2 · Cited by 5
Editorial for Special Issue: The Chorioallantoic Membrane (CAM) Model—Traditional and State-of-the Art Applications: The 1st International CAM Conference
Schneider‐Stock, R., & Flügen, G. (2023) · Cancers · doi:10.3390/cancers15030772 · Cited by 5
Advancing oral squamous cell carcinoma research: the evolving role of patient-derived cell lines, xenografts, and organoid models
Upadhyay, V., Das, S., Nehru, A., Swetha, U. S., Vatsa, P. P., Chamoli, A., & Mandoli, A. (2025) · 3 Biotech · doi:10.1007/s13205-025-04472-6 · Cited by 4
“Despite extensive preclinical testing in these systems, many drug candidates ultimately fail in clinical trials due to poor efficacy or unforeseen toxicity (Arrowsmith and Miller 2013).”
Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma
Suzuki, T., Heishima, K., Yamazaki, J., Yamazaki, M., Kinoshita, R., Sangho, K. I. M., Hosoya, K., Okamatsu‐Ogura, Y., Sasaki, M., Xu, P., et al. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1734339 · Cited by 3
“This makes it difficult to predict patient responses (67, 68).”
Engineering the Human Endometrial–Embryo Interface: Breakthroughs in 3D Uterine Models
Douglas, J. A., Higgins, J., Wimalasiri, D. H., Winship, A., & Fitzgerald, H. C. (2026) · Biomolecules · doi:10.3390/biom16030383 · Cited by 6
“The clinical relevance of cancer cell lines for chemotherapeutic screening has been a subject of debate previously [116], with drug responses of many cell lines failing to be recapitulated in clinical trials [117].”
Advancements in 3D in vitro Cell Culture Systems: Enhancing Drug Pharmacokinetics and Toxicity Assessment in Pharmaceutical Development
Bayraktaroğlu, K., Bal, E., & Rencüzoğulları, Ö. (2024) · International Journal of Life Sciences and Biotechnology · doi:10.38001/ijlsb.1493377 · Cited by 4
Skin-on-Chip
Chaturvedi, D., Mukherjee, S., Sawant, P., Jain, P. D., & Majumder, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-1379-2_22 · Cited by 5
Tumor-on-a-Chip: Microfluidic Models of Hypoxic Tumor Microenvironment
Parihar, A., Choudhary, N. K., Parihar, D. S., & Khan, R. (2023) · Springer eBooks · doi:10.1007/978-981-99-0313-9_14 · Cited by 8
The Discovery and Development of Eg5 Inhibitors for the Clinic
Good, J. A. D., Berretta, G., Anthony, N. G., & Mackay, S. P. (2015) · Springer eBooks · doi:10.1007/978-94-017-9732-0_2 · Cited by 4
Conquering the barriers: are antibody therapeutics feasible for CNS indications?
Stanimirovic, D. B., & Kemmerich, K. (2015) · Future Neurology · doi:10.2217/fnl.15.3 · Cited by 5
Drug Classification and Drug Disposition Prediction
Hosey, C. M., & Benet, L. Z. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12375-3 · Cited by 5
“In fact, pharmacokinetics was once a leading cause of drug failure during development, but is no longer a significant concern due to our improved understanding of drug disposition.(3,4) During development, it is advantageous to harness drug disposition predictions using preclinical models, including in silico, in vitr…”
Background
Using intermediate cognitive endpoints to facilitate translational research in psychosis
Gilmour, G., Gastambide, F., Marston, H. M., & Walton, M. E. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.04.011 · Cited by 4
“The need for improved translational validity has been borne from analysis of recent clinical failures in neuropsychiatric drug discovery, where lack of demonstration of target engagement and/or any measure of efficacy has been a worryingly pervasive concern [22].”
Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events
Duke, S. P., Kleoudis, C. S., Polinkovsky, M., et al. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-016-0176-0 · Cited by 4
“There are many challenges during drug development where safety-related issues continue to be a major cause of drug attrition in preclinical and clinical phases [1].”
Background
Application of Spermatogonial Transplantation in Agricultural Animals
González, R., Tang, L., & Dobrinski, I. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7505-1_14 · Cited by 4
Histograms of Frequency-Intensity Distribution Deep Learning to Predict the Seizure Liability of Drugs in Electroencephalography
Matsuda, N., Kinoshita, K., Okamura, A., Shirakawa, T., & Suzuki, I. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab061 · Cited by 4
Considerations towards the better integration of epidemiology into quantitative risk assessment
Déglin, S. E., Burstyn, I., Chen, C. L., Miller, D. J., Gribble, M. O., Hamade, A. K., Chang, E. T., Avanasi, R., Boon, D., & Reed, J. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100084 · Cited by 5
“However, there is growing concern about the ability of laboratory animals, particularly rodents, to accurately predict human outcomes [13,14].”
[Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
Pauli, C., Moch, H., & Rubin, M. A. (2017) · doi:10.7892/boris.110750 · Cited by 4
Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy
Bera, T. K., Liu, W., Leshem, Y., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000263 · Cited by 4
Dissociation of mGlu2/3 agonist effects on ketamine-induced regional and event-related oxygen signals
François, J., Gastambide, F., Conway, M. W., Tricklebank, M. D., & Gilmour, G. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3948-4 · Cited by 4
An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders
Barajaz, A. M., & Kliethermes, C. L. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.022 · Cited by 4
Statistical Techniques in Pharmaceutical Product Development
Barua, A., Deb, P. K., Maheshwari, R., et al. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814421-3.00010-5 · Cited by 4
Experimental Screening Strategies to Reduce Attrition Risk
Peakman, M., Troutman, M. D., Gonzales, R., & Schmidt, A. W. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch7 · Cited by 6
Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products
Selen, A., Müllertz, A., Kesisoglou, F., Ho, R. J. Y., Cook, J., Dickinson, P. A., & Flanagan, T. R. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00534-0 · Cited by 5
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 3
“Additionally, most drugs in the pipeline do not make it, with a failure rate estimated at nearly nine out of ten drugs [9, 10].”
Identifying Novel Proteins for Chronic Pain: Integration of Human Brain Proteomes and Genome-wide Association Data
Huang, H., Ji, F., Hu, C., Huang, J., Liu, F., Han, Z., Liu, L., Cao, M., & Fu, G. (2024) · Journal of Pain · doi:10.1016/j.jpain.2024.104610 · Cited by 4
Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug Development
Albert, V., Skinner, D., Karnwal, S., Guili, L. N., Vazquez, M., Ledezma, O., Shaffer, R., Celniker, A., Cruz, A. D. L., Caliendo, M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00452 · Cited by 2
Pricing pharmaceutical compounds under development
Dimitri, N. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.006 · Cited by 3
The use of phase 2 interim analysis to expedite drug development decisions
Huang, J., Das, A., Burger, H. U., Zhong, W. H., Zhang, W., & Liebérman, G. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.05.006 · Cited by 3
“Despite advantages conferred by programs designed to accelerate clinical development and regulatory review of marketing applications, average development times for oncology drugs in the United States are longer than those for non-oncology drugs, with high reported rates of failure [2–5].”
Background
La reproducibilidad de las investigaciones biomédicas: Quo vadis?
Dal‐Ré, R., Bernad, A., & Garesse, R. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2015.11.029 · Cited by 3
Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening
Williams, J. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_10 · Cited by 3
Commercial and regulatory challenges in cancer nanomedicine
Fateh, S. T., Fateh, S. T., Salehi-Najafabadi, A., & Aref, A. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00009-4 · Cited by 4
An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates
Haanstra, K. G., Jonker, M., & Hart, B. A. ‘. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00462 · Cited by 3
“J Neuroimmune Pharmacol (2015) 11(1):73–83.”
Method
A comparison of stochastic programming methods for portfolio level decision-making
Graham, E., Jaki, T., & Harbron, C. G. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1684307 · Cited by 3
“The most common reasons for a drug not continuing to the next stage of development are also presented in Table 1, with the most common reason for failure being due to a lack of efficacy (Arrowsmith and Miller 2013). In Phase II, 59% of failures are due to a lack of efficacy and in Phase III this lowers slightly to 52%…”
BackgroundInfluential
Comparison of 2D and 3D cell cultures of colorectal adenocarcinoma as models for drug screening
Poloznikov, A. A., Nikulin, S. V., Болотина, Л. В., et al. (2019) · Russian Chemical Bulletin · doi:10.1007/s11172-019-2716-8 · Cited by 3
Biomarker Exploration and Its Clinical Use
Saito, Y., Sai, K., Kaniwa, N., et al. (2013) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.13-00232-2 · Cited by 3
Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure
Takahashi, R., Ichikawa, H., & Kanda, K. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.12.001 · Cited by 3
“In recent years, two of the primary factors behind the current low clinical success rate of drug candidates (~11%) [13] are lack of efficacy (56%) and safety issues (28%) [2], which have been first detected in the late clinical study stages of the drug development process.”
Background
Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders
Egli, M., White, D. A., & Acri, J. B. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.007 · Cited by 3
Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment
Armstrong, D., Li, S., Frieauff, W., Martus, H. ‐., Reilly, J., Mikhailov, D., Whitebread, S., & Urbán, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12367-4 · Cited by 3
Development of Human Target Validation Classification that Predicts Future Clinical Efficacy
Karlsson, C., Greasley, P. J., Gustafsson, D., & Wåhlander, K. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250894 · Cited by 3
“, 2011) and most of the late-phase failures are due to lack of efficacy (Arrowsmith and Miller, 2013; Cook et al., 2014; Hay et al., 2014).”
Background
The determinants of attrition in drug development: a duration analysisPreprint
Barrenho, E., Smith, P., & Miraldo, M. (2013) · RePEc: Research Papers in Economics · doi:10.25561/12204 · Cited by 3
Multiomic Underpinnings of Drug Targets for Intracranial Aneurysm: Evidence From Diversified Mendelian Randomization
Fan, Y., Lu, D., Yang, C., Song, Z., Chen, Y., Ma, Y., Li, J., & Zhang, H. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70430 · Cited by 2
The transformative role of single-cell analysis in multifactorial disorders research
Wang, C., Ko, C.-C., Kumar, S., Xuan, D. T. M., Lin, H.-R., Lee, Y.-K., Nguyen, N. U. N., Pei-Ming, Y., & Solomon, D. D. (2026) · Methods · doi:10.1016/j.ymeth.2026.03.009 · Cited by 3
Human iPSC-derived and conventional cancer models in precision oncology: advancing patient-specific therapies from bench to bedside
Pant, T., Brajesh, R. G., Day, B. W., Solomon, A. D., Juric, M., Zielonka, J., & Bai, X. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03694-7 · Cited by 2
Subset binding enables detection of multimodal patient subgroup patterns and drug target discovery in idiopathic pulmonary fibrosis
Natsume‐Kitatani, Y., Itoh, M. N., Takeda, Y., et al. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag153 · Cited by 2
“In drug discovery, one of the major challenges is the high failure rate of proof of concept (POC) in Phase II clinical trials, largely owing to the lack of significant efficacy [1].”
NIH will partner drug industry to study Alzheimer's, diabetes, and autoimmune disorders
McCarthy, M. R. (2014) · BMJ · doi:10.1136/bmj.g1397 · Cited by 2

Authors: Arrowsmith, J., & Miller, P.
Affiliations: Thomson Reuters (United Kingdom) (GB)
Corresponding author: Miller, Philip
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2013-08
Volume: 12
Issue: 8
Pages: 569-569
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd4090
OpenAlex: W1968779484
Cited by: 697
References: 0
Citations by year: 2026: 42 · 2025: 35 · 2024: 45 · 2023: 48 · 2022: 38 · 2021: 55 · 2020: 51 · 2019: 59 · 2018: 57 · 2017: 61 · 2016: 74 · 2015: 63 · 2014: 39 · 2013: 30
Type: other
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords: attrition rates, drug development, clinical trial failure, drug discovery pipeline
MeSH terms: Humans, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Early Termination of Clinical Trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase II and Phase III attrition rates 2011–2012

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks